(MENAFN) Danish Novo Nordisk announced that it would invest USD224 million in a new facility manufacturing products for treating haemophilia, a disease of bleeding disorder, Xinhua reported.
The pharmaceutical company said the facility is expected to be approved and fully operational in 2020. Groundbreaking for the facility took place in Kalundborg, some 100 km west of the capital city of Copenhagen.
"The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark," executive vice president of Novo Nordisk Product Supply said in a statement.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.